<DOC>
	<DOC>NCT00723710</DOC>
	<brief_summary>Patients with malignant melanoma who had undergone surgery will receive adjuvant treatment with high-dose Intron A for one year. The objective of this study is to maximize treatment compliance by proactive management of side effects in a day-to-day healthcare setting.</brief_summary>
	<brief_title>Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Signed informed consent Age &gt; 18 years Confirmed melanoma Patient has been prescribed Intron A therapy for HighRisk Stage II &amp; III Melanoma Intron A therapy started within 70 days of surgery (additional 15 days may be granted by the sponsor upon written approval) Proper contraception in both male and female subjects and the female partner(s) of male study subjects Metastatic disease at the time of diagnosis Other malignancies History of non compliance to other therapies Pregnancy or breast feeding Previous Intron A therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>